Patrick Cobb, MD
Hematology & Oncology · Billings, MTNPI 1710968219
Payments from drug & device makers
Across 1,849 payments — averaging $7963.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$6.9M
- Genentech, Inc.$1.3M
- Seagen Inc.$855K
- Novartis$805K
- AbbVie$483K
- Pfizer$417K
- plus $4M from 40 others
Across 26 payments — averaging $369.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$6K
- Regeneron$2K
- EMD Serono, Inc.$1K
- Eli Lilly$291
- AbbVie$205
What the payments were for
- Consulting fees$13,36964%
- Travel & lodging$3,15615%
- Food & beverage$4,33321%
- Education$820%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,724,984 in reported general payments places this provider in the 95th percentile of 37 hematology & oncology providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 62 | $745,690 |
| RevlimidLenalidomide | 33 | $614,194 |
| TasignaNilotinib Hcl | 22 | $369,777 |
| IbrancePalbociclib | 24 | $360,064 |
| XtandiEnzalutamide | 24 | $315,848 |
| KisqaliRibociclib Succinate | 20 | $288,628 |
| OnuregAzacitidine | 11 | $263,299 |
| WeliregBelzutifan | 12 | $250,227 |
| Lenalidomide | 14 | $171,131 |
| NubeqaDarolutamide | 17 | $153,119 |
| CalquenceAcalabrutinib Maleate | 11 | $129,983 |
| OxycontinOxycodone Hcl | 21 | $92,620 |
| Abiraterone Acetate | 27 | $51,401 |
| Imatinib Mesylate | 35 | $50,498 |
| OrgovyxRelugolix | 12 | $30,252 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $5,460 | $745,69062 claims |
| NovartisTasigna, Kisqali | $805,454 | $658,40542 claims |
| Bristol Myers SquibbRevlimid | $63,615 | $614,19433 claims |
| PfizerIbrance, Eliquis | $416,694 | $382,24159 claims |
| E.r. Squibb & Sons, L.L.C.Onureg | $150,308 | $263,29911 claims |
| MerckWelireg | $6,889,826 | $250,22712 claims |
| BayerNubeqa | $79,064 | $153,11917 claims |
| AstraZenecaCalquence | $397,889 | $129,98311 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $31,700 | $30,25212 claims |
| AbbVieCreon | $483,292 | $18,18417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 37 hematology & oncology providers in Montana.
Other hematology & oncology in Billings
- Benjamin MarchelloBillings$68K
- Michael KiddBillings$33K
- Brock WhittenbergerBillings$5K
- Martin LucasBillings$187
- David ChristiansonBillings$163
- Troy FiddlerBillings$75
- Grant HarrerGreat Falls$236K
- Dhimant PatelBozeman$233K
- Karl GuterGreat Falls$200K
- Elise AnderesKalispell$140K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.